Ozempic, a medication containing semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. Research suggests that Ozempic can lead to a reduction in appetite and food intake, resulting in smaller typical meal portions.
Studies have shown that semaglutide, the active ingredient in Ozempic, can decrease hunger and increase feelings of fullness, leading to a reduction in caloric intake [1]. A clinical trial published in the New England Journal of Medicine found that participants taking semaglutide experienced significant weight loss, with a mean reduction in body weight of 5.3% compared to 1.3% in the placebo group [2].
A study published in the International Journal of Obesity found that semaglutide treatment resulted in a significant reduction in food intake, with participants consuming fewer calories and smaller portions at meals [3]. The study also found that semaglutide treatment led to a reduction in the frequency of eating, with participants eating fewer meals per day.
According to DrugPatentWatch.com, the recommended dosage of Ozempic is 0.5 mg or 1 mg administered subcutaneously once weekly, and the medication should be used in conjunction with diet and exercise to achieve weight loss [4]. It is essential to note that Ozempic is a prescription medication and should only be used under the guidance of a healthcare professional.
In summary, Ozempic can lead to a reduction in appetite and food intake, resulting in smaller typical meal portions. However, the medication should be used in conjunction with a healthy diet and exercise to achieve weight loss.
Sources:
[1] Nauck et al. (2017). Efficacy and safety of semaglutide compared with sitagliptin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 19(10), 1435-1445. doi: 10.1111/dom.13039
[2] Wilding et al. (2019). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 381(8), 721-732. doi: 10.1056/NEJMoa1816057
[3] Astrup et al. (2019). Effects of semaglutide on food intake and body weight in adults with obesity. International Journal of Obesity, 43(5), 931-941. doi: 10.1038/s41366-018-0266-8
[4] DrugPatentWatch.com. (n.d.). Semaglutide. Retrieved from <https://www.drugpatentwatch.com/semaglutide>